A fractional CMO practice · Florida regenerative medicine

Predictable cash-pay revenue. Defensible compliance posture. One Fractional CMO.

The fractional CMO practice for Florida regenerative medicine clinics. Built around the outcomes physician-led clinics actually need — without the agency overhead or the compliance gaps.

No full-time CMO hire. No outsourced agency. One fractional CMO with thirty years of healthcare commercialization, amplified by HealthFounderOS — the AI operating system that gives one operator the leverage of a team.

Who
Physician-led regen practices$100K–$500K/mo
Exclusivity
One practice per MSAPer category cluster
Modalities
Cell · Gene · LongevityDefensible pathways only
Posture
Documented frameworkSB 1768 · FDA · FTC
The regulatory layer, built in. Every asset, every vendor, every call — audited against the framework before it ships.
FDA 21 CFR 1271 aware SB 1768 operating posture FTC substantiation standard Vendor diligence gate Sub-type pathway analysis
02The Problem

Three patterns we see in nearly every regenerative clinic at this stage.

Most regenerative practices in Florida that have crossed $100K/month start to plateau in the same place: a backlog of consults that don't convert, a marketing budget that can't be tied to revenue, and a growing suspicion that the practice's growth ceiling is the practice's sales process — not its lead volume.

The conventional response is more leads. More Meta ads, more landing pages, more retargeting. It rarely fixes the problem, because the problem isn't lead volume. The problem is that a $15,000 cash-pay regenerative protocol is the highest-consideration purchasing decision most of these patients will ever make — and most practices are running it through an intake process designed for $40 copays.

Underneath the conversion problem is a second one most operators don't see until it bites: the regulatory environment around regenerative medicine has tightened. The FTC's January 2025 settlement with the Stem Cell Institute of America named the marketing services company as a co-defendant. SB 1768 brought new advertising disclosure requirements in Florida. The August 2025 FDA Warning Letter to Innate Healthcare Institute is the most recent example of homologous-use enforcement. Practices that grew quickly with aggressive marketing are now liabilities, not assets.

What we hear most often

  • "We're spending more on ads but consults aren't converting"
  • "My intake team can't handle a $15K conversation"
  • "We don't know what we can and can't say in our marketing"
  • "Our growth is real but I'm not sure it's defensible"
  • "I'm watching competitors get in trouble and I don't know if we're next"
03The Reframe

Where most clinics are putting their attention — and where they should be.

The practice has the therapy. The practice has the patients. What it doesn't have is the close. That's not a marketing failure — it's a system failure, and it shows up at the moment a patient says "that's a lot of money."

Patients who reject the price aren't broke. The patient population for a regenerative protocol is, on average, more financially capable than a typical insurance-billed visit. They reject the price because they don't yet believe the therapy is worth the price — and the practice hasn't built the system that converts that belief.

Belief in this category isn't built by the ad. It's built by the physician's authority, by clinical evidence presented in a way the patient can absorb, by an intake conversation that earns trust before it asks for a credit card, and by a follow-up sequence that handles the inevitable second-thoughts in the 48 hours after the consult. That's the system most regenerative practices don't have. That's the system this practice builds.

"Your patients can afford the therapy. They just don't believe it yet."
The operating principle
04The System

What we build, and why.

A three-step sequence that converts cash-pay revenue, sitting on top of the compliance layer that keeps the practice defensible. Same architecture every engagement; depth of buildout depends on the tier.

01
Pre-qualify on belief

Physician-led webinars

An evergreen and live webinar system that positions the owner-physician as the clinical authority and pre-qualifies patients on belief — that the therapy is worth the price — before they ever book a consultation. Educational, evidence-based, clinician-delivered.

02
Convert the consult

Sales intake coaching

Coaching for the front-of-house team — intake coordinators, practice managers, anyone who runs the first ten minutes. The single highest-leverage conversion layer in a regenerative practice. Most never get formal training on the specific dynamics of a $15,000 conversation.

03
Close the cash-pay

Close-call framework

The physician version of a high-consideration sales conversation. Tuned to the specific protocol, the specific objections, the specific price-justification mechanics that come up at $10,000 to $50,000 cash-pay. Not a script — a framework the physician owns and runs.

The foundation

Compliance spine — under all three steps.

FDA 361 vs. 351 awareness, FTC substantiation standards, SB 1768 statutory disclosures, vendor diligence on every third-party tool, quarterly audit cadence. Built so the practice survives the regulatory environment, not just operates inside it. Documented and operational.

05Engagements

Three engagement formats. One operator on every call.

Every engagement begins with a Discovery and Onboarding call. From there, one of three formats — depending on the practice's stage, capacity, and ambition.

Tier 01 · Blueprint

Do it yourself

90-day diagnostic-and-design

The complete marketing and sales plan, compliance posture review, and playbooks. Your team executes.

  • Full diagnostic + positioning
  • 12-month growth plan
  • Qualification and close-call frameworks
  • Compliance posture review
Best for practices with marketing capacity that need the strategy and the guardrails — not the hands.
Tier 03 · Elite

Done for you

12-month embedded engagement

We own marketing, own the top of the sales funnel, integrate with intake. Includes AI voice-agent deployment under the vendor compliance gate.

  • Embedded execution
  • Intake team integration
  • AI voice agent (gated)
  • Monthly compliance audit
For owner-physicians who want to stop running growth entirely and focus on clinical work and exit readiness.
06On The Record

Direct feedback from healthcare CEOs and founders.

A selection of direct client commentary from the principal's broader healthcare commercialization work — biotech, diagnostics, digital health, and consumer health launches. Names withheld; roles retained for context. Offered as a read on how the principal operates — not as a claim of typical results for this specific practice.

Delivered a great quantitative approach to our commercial planning — solid modeling to inform our DTC expectations on getting engagement and sales up.

President & CEOCognitive diagnostics company

A great partner with solid strategy and creative chops. The ideation and creative concepting helped us rethink our go-to-market story with much greater potential to break through in a crowded market.

Founder & CEOConsumer health brand

Expertise is nothing short of remarkable. Invaluable insights and direction — same day. An innate talent for productivity and execution. Fresh ideas, practical and impactful.

Founder & CEODigital health platform

Advocates for a tight link between marketing, sales, and service. Gets human-to-human connections as an advertiser — and building out AI capabilities to automate the workflows. Best of both worlds.

Founder & CEOHealthcare consulting firm

Testimonials are verbatim excerpts from prior engagements across the principal's 30+ year healthcare commercialization career. Full, attributed versions are available on request under NDA. These statements are not endorsements of the PredictCare.ai Regenerative Medicine Growth Practice specifically, and do not reflect typical results for any particular engagement.

07Is This Right For You

We work with a specific kind of regenerative clinic.

We are deliberate about who we work with. The ICP is narrower than "anyone in regenerative medicine" because the regulatory exposure of the wrong client engagement is too high to be casual about it.

This is for you

  • You are physician-owned, or have a Florida-licensed MD, DO, or DPM as medical director with operational clinical control
  • You run a regenerative practice — a stand-alone longevity clinic, a stem cell clinic, or a specialty practice (orthopedics, pain, wound, sports, podiatry, dermatology, rheumatology) adding regenerative therapies
  • You're at $100K–$500K/month and the cash-pay close rate is the ceiling on the practice, not lead volume
  • You have a real clinical protocol per therapy — not a menu of what the patient asks for
  • Your pathway fits a defensible route: PRP / BMAC, 361 HCT/P (minimally manipulated, homologous use), SB 1768 scope (orthopedics, wound, pain), an active IND, or standard-of-care augmentation (longevity)
  • You want your marketing to strengthen your compliance posture, not weaken it

This is not for you

  • Chiropractor-led, NP-led, or PA-led regenerative practices
  • IV-drip storefronts or med-spa hybrids without a physician protocol owner
  • Any practice marketing unapproved stem cell therapies with disease-cure claims (Parkinson's, MS, autism, dementia, ALS, etc.)
  • Practices with unresolved FDA warning letters, FTC inquiries, or state AG actions
  • Neurology, disease-focused cardiology, oncology — the FDA/FTC enforcement hot zones; we decline regardless of credentials or funding
  • Anyone looking for cold outbound, prospect-list dialing, or lead-gen theater
08Who Is Behind This

About the principal.

The Principal
Practice Lead · Regenerative Medicine Growth Practice · Operator of HealthFounderOS

Healthcare commercialization operator. Active Center-of-Excellence work in regenerative medicine. CLTI / ACP-01 fluency. Prior leadership across 15+ healthcare product launches at Seagen, Alexion, Merck, AbbVie, Pfizer and more.

30+
Years in healthcare
$500M+
Commercial impact
15+
Product launches
1:1
Direct on every call

Most consultants in the regenerative space learned the category from a course, a YouTube channel, or a single engagement they now publish case studies about. The category grew faster than operator depth could keep up with.

This practice is the other thing. Built by an operator who has spent three decades commercializing healthcare products — inside companies, inside Centers of Excellence, and inside the clinical-regulatory conversation that determines whether a product ever reaches the patient it was designed for. The framework wasn't repackaged for a new vertical. It was built inside the vertical.

Every Discovery and Onboarding call is with the principal directly. No junior account manager reading slides. No discovery form that routes to a sales rep. The person who built the system is the person you talk to.

09The Process

Discovery. Design. Deploy.

01

Discovery

A 30-minute call. We discuss your practice's current state, audit your growth system at a high level, and confirm whether your pathway, modalities, and market are a fit. Free. Direct. With the principal.

02

Design

If there's a fit, we map the 90-day plan and the tier it belongs in. If there isn't — including for regulatory reasons — we say so plainly and recommend where to go instead.

03

Deploy

Blueprint executes inside your team. Partnership runs as a weekly operating cadence. Elite embeds entirely. Every engagement includes the compliance audit cadence from day one.

10Take the Next Step

Start with a Discovery and Onboarding call.

Three ways to engage, in order of commitment. Start with the one that fits where you actually are.

One practice per market · Availability confirmed on the call